You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

  • Authors: Edith Perez, MD; Neelimua Denduluri, MD; Maire Patterson, BSN, RN, OCN
  • CME / ABIM MOC / CE Released: 6/13/2019
  • Valid for credit through: 6/13/2020
Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, surgeons, and nurses/advanced practice nurses.

The goal of this activity is to increase clinicians' knowledge and competence about the use of newer therapies in patients with human epidermal growth factor receptor (HER)2-positive early breast cancer.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Safety and efficacy data on key novel and emerging agents for early-stage HER2-positive breast cancer (BC)
  • Have greater competence related to:
    • Individualizing adjuvant therapy based on patient and tumor factors in patients with early-stage HER2-positive BC
    • Coordination of care within the interdisciplinary BC treatment team
  • Have greater confidence related to:
    • Using strategies to help engage patients with HER2-positive BC in their treatment selection and ongoing


The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.


  • Edith A. Perez, MD

    Serene M. and Frances C. Durling Professor of Medicine
    Mayo Clinic
    Jacksonville, Florida


    Disclosure: Edith Perez, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Daiichi Sankyo, Inc.; Genentech, Inc.; Puma Biotechnology, Inc.; Seattle Genetics, Inc.
    Owns stock, stock options, or bonds from: Roche

  • Neelimua Denduluri, MD

    Associate Chair
    US Oncology Breast Research Virginia Cancer Specialists
    US Oncology Network
    Arlington, Virginia


    Disclosure: Neelimua Denduluri, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Daiichi Sankyo, Inc.
    Received grants for clinical research from: Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.

  • Maire Patterson, BSN, RN, OCN

    Registered Nurse
    Virginia Cancer Specialists
    Arlington, Virginia


    Disclosure: Maire Patterson, BSN, RN, OCN, has disclosed no relevant financial relationships.


  • Angela Zimmermann, PhD

    Scientific Content Manager, Medscape, LLC


    Disclosure: Angela Zimmermann, PhD, has disclosed the following relevant financial relationships:
    Developed content for IME or CPD activities supported by: Astra Zeneca; Merck; Novartis; Pfizer

CME Reviewer(s)

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer

Authors: Edith Perez, MD; Neelimua Denduluri, MD; Maire Patterson, BSN, RN, OCNFaculty and Disclosures

CME / ABIM MOC / CE Released: 6/13/2019

Valid for credit through: 6/13/2020


A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print